AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

XERS · NASDAQ · Biotechnology

Xeris Biopharma

Markets Recorlev, Gvoke and Keveyis while advancing formulation-based drug programs.

$8.48

After-hours close+0.00 (+0.06%)

At close$8.48(−1.45%)

Something off on this page? Send us feedback.

Profile

Xeris Biopharma Holdings, Inc.XERSHealth Care

Markets a U.S.-focused specialty portfolio across Cushing's syndrome, severe hypoglycemia, and primary periodic paralysis, with Recorlev, Gvoke, and Keveyis as the current products. A single reporting segment ties commercial execution to XeriSol and XeriJect formulation technology and partner development work.

Markets a U.S.-focused specialty biopharma portfolio anchored by Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. The business reports as one segment across chronic endocrine and neurological diseases.

Commercial execution is centered on specialty sales and product access, with a larger sales-and-marketing footprint than research organization. XeriSol and XeriJect formulation technology support internal candidates such as XP-8121 and partner programs.

The model depends on U.S. reimbursement, FDA-regulated product claims, and outside suppliers and manufacturers. Keveyis faces generic and branded-generic dichlorphenamide competition, while Recorlev's U.S. orphan exclusivity currently extends later than Keveyis' exclusivity.

Company facts

CEOJohn P. Shannon

ListedOct 6, 2021

ExchangeNASDAQ

HeadquartersChicago, IL

CountryUnited States

Employees435

CIK0001867096

ISINUS98422E1038

Key statistics

Market cap$1.46B

EPS (ttm)−$0.1029

P/E (ttm)−82.41

ROE-426.3%

P/B−150.56

P/S4.36

Dividend yield—

Beta0.79vs XLV 0.28

Year to date +15.3% · Average volume (30d) 1.6M

Analysts

Price target, next 12 months$12.00+41.5%Median of 11 analysts · vs the Aug 28 close

ConsensusBuy10 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $8.48

High$12.00+41.5%

Median$12.00+41.5%

Low$12.00+41.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 20, 2026	Barclays	Reiterate		Overweight	$9	$12
Dec 8, 2025	Barclays	Target				$9
Oct 29, 2025	Oppenheimer	Reiterate		Outperform	$5	$18
Nov 11, 2024	Piper Sandler	Downgrade	Overweight	Neutral

Earnings

EPS

Estimate$0.02

ReportedDue Nov 5, 2026

Revenue

Estimate$101.6M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.01	−$0.18	−1,582.7%	$90.1M	$91.0M	+1.0%	−9.25%
May 7, 2026Q1 FY26	$0.00	$0.01	—	$79.8M	$82.5M	+3.3%	−1.51%
Mar 2, 2026Q4 FY25	$0.03	$0.06	+100.0%	$82.2M	$85.8M	+4.4%	−1.33%
Nov 6, 2025Q3 FY25	$0.01	$0.00	−65.0%	$86.0M	$74.4M	−13.5%	−3.63%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$60.1M	$71.5M	$74.4M	$85.8M	$83.1M	$92.1M
Gross profit	$51.4M	$56.9M	$63.4M	$66.7M	$69.8M	$79.6M
Operating income	−$3.1M	$4.5M	$6.7M	$16.8M	$7.9M	$5.2M
Net income	−$9.2M	−$1.9M	$621.0K	$11.1M	$2.2M	−$31.1M
Diluted EPS	−$0.06	−$0.01	$0.00	$0.06	$0.01	−$0.18
Gross margin	85.5%	79.6%	85.2%	77.8%	84.0%	86.4%
Operating margin	-5.1%	6.3%	9.0%	19.5%	9.5%	5.6%

Fiscal years (4-quarter sums)FY21 $49.8M · FY22 $110.2M · FY23 $163.9M · FY24 $203.1M · FY25 $291.8M

Revenue by product · Q2 FY26

Product$91.0M · 89%

Keveyis$11.7M · 11%

Balance sheet, Jun 30, 2026Cash & short-term investments $121.7M · Total debt $289.4M · Total assets $411.9M · Shareholders' equity −$9.7M

Dividends

No dividends on record.

Ownership

Institutions 64.29%111.00M sharesInsiders 5.28%9.12M sharesOther 30.43%52.53M shares

Shares outstanding 172.64M · Float 164.66M · 95.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	14.53M	8.41%	13F	Aug 7, 2026
Vanguard Capital Management	8.64M	5.00%	13G	Jul 31, 2026
D. E. Shaw & Co., Inc.	7.80M	4.52%	13F	Aug 14, 2026
State Street Corp	4.82M	2.79%	13F	Aug 7, 2026
Geode Capital Management, LLC	4.72M	2.73%	13F	Aug 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 12, 2026	Steven Pieper	officer: See Remarks	−5,000	$8.50
Aug 3, 2026	Beth Hecht	officer: See Remarks	−16,666	$8.01
Aug 3, 2026	Kevin McCulloch	officer: See Remarks	−15,000	$8.02
Jul 7, 2026	Steven Pieper	officer: See Remarks	−27,600	$8.52
Jul 6, 2026	Steven Pieper	officer: See Remarks	−17,400	$8.50